Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002552022 | SCV003459779 | uncertain significance | not provided | 2023-03-04 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 967 of the CFH protein (p.Gly967Glu). This variant is present in population databases (rs375951438, gnomAD 0.004%). This missense change has been observed in individual(s) with age-related macular degeneration (PMID: 29686068). ClinVar contains an entry for this variant (Variation ID: 829889). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV002552022 | SCV003831615 | uncertain significance | not provided | 2020-03-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001029836 | SCV004177362 | uncertain significance | Hemolytic uremic syndrome, atypical, susceptibility to, 1 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003456176 | SCV004177363 | uncertain significance | Age related macular degeneration 4 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003455142 | SCV004177364 | uncertain significance | Basal laminar drusen | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003455141 | SCV004177365 | uncertain significance | Factor H deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030907 | SCV004923723 | uncertain significance | Inborn genetic diseases | 2024-01-04 | criteria provided, single submitter | clinical testing | The c.2900G>A (p.G967E) alteration is located in exon 18 (coding exon 18) of the CFH gene. This alteration results from a G to A substitution at nucleotide position 2900, causing the glycine (G) at amino acid position 967 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV001029836 | SCV001192621 | uncertain significance | Hemolytic uremic syndrome, atypical, susceptibility to, 1 | 2019-08-28 | no assertion criteria provided | clinical testing |